336539
A multi-country look at care and implications of diabetic retinopathy and vision impairment: Perspectives of adults with diabetes and health care providers
Methods: Qualitative interviews were conducted with 73 people with diabetes (PWD) and 48 providers in eight countries, which were selected for geographic and economic variability. Almost one-half of the PWD (45%) had DR. Interviews focused on knowledge, attitudes, service availability and use – and factors that impact them.
Findings: Approximately 20% of PWD were unaware that vision loss can be a complication of the disease—or had been unaware until they faced vision issues themselves. Both PWD and providers indicated that in a number of cases, awareness about the risk of vision impairment was insufficient to motivate PWD to visit an eye specialist, especially in the absence of symptoms. Referral delays and absence of a proactive referral process were also noted. Long waits for service and crowding affected access, particularly in low-income countries. Participants with DR and experiencing impaired vision reported: job loss and resultant economic hardships; limitations on travel, independence and recreational activities; and challenges to disease management, including self-monitoring.
Conclusion: DR progression, vision loss and the consequences thereof may be reduced with more effective messaging regarding risk, improved referral systems, and improved access to care—particularly in low-income countries.
Learning Areas:
Chronic disease management and preventionLearning Objectives:
Describe perspectives on care and its impact on diabetic retinopathy and vision impairment in eight countries.
Keyword(s): Diabetes, Vision Care
Qualified on the content I am responsible for because: I am a research coordinator of the Diabetic Retinopathy Barometer Project, and have been involved in data collection, analysis, and dissemination of findings since its inception.
Any relevant financial relationships? Yes
Name of Organization | Clinical/Research Area | Type of relationship |
---|---|---|
Bayer Pharma AG | Pharmaceutical | Funder |
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.